Forest Namenda Has 10% Off-Label Use In Mild-To-Moderate Alzheimer’s
Executive Summary
Forest's Alzheimer's disease agent Namenda has 10% off-label use based on early launch data
You may also be interested in...
Forest Sees “Moderate” Namenda Growth Opportunity In Mild Alzheimer’s
Forest expects approval of its Namenda sNDA for the treatment of mild-to-moderate Alzheimer's disease to generate a "modest uptick" in prescription volume in the second half of the year
Forest Sees “Moderate” Namenda Growth Opportunity In Mild Alzheimer’s
Forest expects approval of its Namenda sNDA for the treatment of mild-to-moderate Alzheimer's disease to generate a "modest uptick" in prescription volume in the second half of the year
Forest Expects Lexapro To Gain Market Share Despite Lilly Cymbalta Launch
Forest is expecting continued market share gains for Lexapro as it prepares for the upcoming launch of Lilly's antidepressant Cymbalta